This article summarized the latest R&D progress of gemcitabine hydrochloride, the Mechanism of Action for gemcitabine hydrochloride, and the drug target R&D trends for gemcitabine hydrochloride.

Freeline Therapeutics reported positive preliminary results on safety, tolerability, and enzyme action from their ongoing Phase 1/2 GALILEO-1 study evaluating FLT201, their gene therapy candidate for Gaucher disease.

More than one encoding rule for CDR sequences is required to reduce the risk of missing FTO sequences in antibody searches.

This article summarized the latest R&D progress of granisetron hydrochloride, the Mechanism of Action for granisetron hydrochloride, and the drug target R&D trends for granisetron hydrochloride.

Disease-Specific Survival (DSS) refers to deaths caused specifically by a particular disease.

Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.

Milestone survival rate is defined as the survival probability at a given point in time.

This article summarized the latest R&D progress of imiglucerase, the Mechanism of Action for imiglucerase, and the drug target R&D trends for imiglucerase.

Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.

This article summarized the latest R&D progress of infliximab-abda, the Mechanism of Action for infliximab-abda, and the drug target R&D trends for infliximab-abda.

Health-Related Quality of Life (HRQoL) is a significant indicator for assessing the quality of life and health status of patients.

Circular RNA (circRNA) is a type of single-stranded RNA with a closed loop structure, initially found in HDV and plant viruses.